Levalbuterol Solution
Product Images NDC 72162-2081

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Levalbuterol (NDC 72162-2081). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622081)

Label for Levalbuterol Inhalation Solution, USP 0.31 mg (0.0103%) in 3 mL sterile unit-dose vials. The package contains 25 vials for respiratory inhalation, relabeled by Bryant Ranch Prepack and manufactured by The Ritedose Corporation. Storage instructions and usage precautions are included on the label.*

FDA Label Image

Chemical Structure (Levalbuterol Inhalation Solution Usp 1)

Chemical structure of Levalbuterol Hydrochloride, depicting its molecular arrangement including aromatic ring, hydroxyl groups, amine group, and hydrochloride component as part of the molecule.*

FDA Label Image

Figure E1 (Levalbuterol Inhalation Solution Usp 10)

An instructional illustration showing parts of a respiratory inhalation device labeled 'Mouthpiece' and 'Reservoir.' The diagram highlights the mouthpiece extending from the device's main body, which includes a cylindrical reservoir.*

FDA Label Image

Figure E2 (Levalbuterol Inhalation Solution Usp 11)

Illustration showing proper fitting of a face mask and attached reservoir used for respiratory inhalation device administration. The image highlights the placement of the face mask and reservoir components, indicating correct assembly for use with an inhalation solution device.*

FDA Label Image

Figure F (Levalbuterol Inhalation Solution Usp 12)

An illustration showing the connection between compressor and nebulizer tubing, indicating how nebulizer tubing attaches to a compressor device for respiratory inhalation treatment.*

FDA Label Image

Figure G1 (Levalbuterol Inhalation Solution Usp 13)

An instructional illustration showing correct placement of a respiratory inhalation solution device. The image labels the mouthpiece and reservoir of the inhaler in relation to a person's mouth, indicating how to use the device for inhalation.*

FDA Label Image

Figure G2 (Levalbuterol Inhalation Solution Usp 14)

An instructional diagram showing the correct use of a respiratory solution inhalation device, highlighting the face mask and the reservoir components for administration of the Levalbuterol solution.*

FDA Label Image

Figure 1 (Levalbuterol Inhalation Solution Usp 2)

A line graph showing mean change in FEV1 over 8 hours for different doses of Levalbuterol and Racemic albuterol compared to placebo. The x-axis represents time in hours, and the y-axis shows the mean percent change in FEV1, with data lines for Lev 1.25 mg, Lev 0.63 mg, Rac 2.5 mg, and placebo (PBO).*

FDA Label Image

Figure 2 (Levalbuterol Inhalation Solution Usp 3)

This line graph depicts the mean change in FEV1 (%) over time (hours) for several treatments, including Levalbuterol at doses 1.25 and 0.63 mg, Racemic albuterol at 2.5 mg, and placebo (PB0). The x-axis represents time in hours from 0 to 8, and the y-axis shows mean percentage change in FEV1 from -5 to 45%. Data points demonstrate higher FEV1 improvement initially with Levalbuterol doses compared to racemic albuterol and placebo.*

FDA Label Image

Figure 3 (Levalbuterol Inhalation Solution Usp 4)

A line graph showing mean change in FEV1 (%) over time (hours) with multiple treatment groups: Lev 0.63 mg, Lev 0.31 mg, Rac 2.5 mg, Rac 1.25 mg, and placebo (Pbo). The graph plots respiratory function changes over a 4-hour period post-treatment.*

FDA Label Image

Figure 4 (Levalbuterol Inhalation Solution Usp 5)

Line graph depicting the mean change in FEV1 (%) over time (hours) for various treatments, including Lev (0.63 and 0.31 mg), Rac (2.5 and 1.25 mg), and placebo (Pbo). The graph shows the response from 0 to 4 hours after administration, with each treatment group represented by different symbols and corresponding sample sizes indicated in the legend.*

FDA Label Image

Figure A (Levalbuterol Inhalation Solution Usp 6)

An instructional diagram showing a unit-dose vial with shaded twist-off tabs on both sides of the vial neck. Text indicates that the shaded areas represent the twist-off tab portions for opening the vial, with arrows pointing to each tab.*

FDA Label Image

Figure B (Levalbuterol Inhalation Solution Usp 7)

An instructional illustration depicting a pouch with a tear seam at the top, labeled 'TEAR AT SEAM' with a downward arrow indicating where to open the package. The pouch appears sealed above the seam line.*

FDA Label Image

Figure C (Levalbuterol Inhalation Solution Usp 8)

An instructional line drawing showing a person using one hand to twist and open a small ampule or vial, likely demonstrating how to prepare a respiratory inhalation solution for administration.*

FDA Label Image

Figure D (Levalbuterol Inhalation Solution Usp 9)

An instructional illustration showing a hand holding a vial labeled "VIAL" above a reservoir labeled "RESERVOIR". The image likely depicts the step of inserting or pouring the vial contents into the reservoir, possibly related to preparing a respiratory inhalation solution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.